Lasmiditan for the Acute Treatment of Migraine
- 12 April 2021
- journal article
- research article
- Published by Taylor & Francis in Pain Management
- Vol. 11 (5) , 437-449
Abstract
Migraine is a leading cause of morbidity and disability worldwide. Triptans were the first migraine-specific drug class developed and have proven efficacy in treatment of this neurological disease.... Lay abstract Migraine is a leading cause of pain and disability worldwide. Triptans (e.g., sumatriptan) were the first migraine-specific drug class developed and have proven to be effective treatme...Keywords
Funding Information
- National Institute of Mental Health
This publication has 63 references indexed in Scilit:
- Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraineNeurology, 2013
- Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the A merican M igraine P revalence and P revention ( AMPP ) StudyHeadache: The Journal of Head and Face Pain, 2013
- Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivityBrain, Behavior, and Immunity, 2012
- Preclinical pharmacological profile of the selective 5-HT1Freceptor agonist lasmiditanCephalalgia, 2010
- Origin of pain in migraine: evidence for peripheral sensitisationThe Lancet Neurology, 2009
- History of Methysergide in MigraineCephalalgia, 2008
- Direct Cost Burden Among Insured US Employees With MigraineHeadache: The Journal of Head and Face Pain, 2008
- Triptans and CNS Side-EffectsCephalalgia, 2004
- Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trialsThe Lancet, 2001
- Biochemical Investigations in Headache: Increase in the Hydroxyindoleacetic Acid Excretion During Migraine AttacksInternational Archives of Allergy and Immunology, 1961